REDWOOD CITY, Calif., Sept. 11, 2015 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from four Oncotype DX® breast cancer studies, including three large clinical outcomes studies in which the test was used to determine treatment, will be presented at the 2015 European Cancer Congress (ECC 2015) in Vienna, Austria, on September 28.
Included in the ECC 2015 program is the first presentation of clinical outcomes results from the large, prospective Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, which was sponsored by the National Cancer Institute (NCI) in the United States and coordinated by the ECOG-ACRIN Cancer Research Group.
Other presentations include results from a large, multi-center five-year patient outcomes review analysis from Clalit Health Services, Israel, in which the Oncotype DX Recurrence Score® results were systematically incorporated in treatment decision making in early-stage, ER-positive, HER2-negative patients. A separate presentation will highlight prospective survival results from the WSG Phase III plan B trial in Germany.
Presentation details are as follows (all times are European Central Time):
Monday, September 28
- Title: "Adjuvant treatment recommendations for ER+ early breast cancer patients by Swiss tumor boards (SAKK 26/10)" (Abstract #1943); B.C. Pestalozzi (Switzerland)
Poster Session Location: Hall C, Poster Board #132
Time: 9:15 – 11:15 a.m.
- Title: "First prospective outcome data in 930 patients with more than 5-year median follow up in whom treatment decisions in clinical practice have been made incorporating the 21-Gene Recurrence Score" (Abstract #1963); S. Stemmer (Israel)
Poster Session Location: Hall C, Poster Board #152
Time: 9:15 – 11:15 a.m.
- Title: "Clinical impact of risk classification by central/local grade or luminal-like subtype vs. Oncotype DX®: First prospective survival results from the WSG Phase III plan B trial" (Abstract #1937); O. Glutz (Germany)
Poster Spotlight Session Location: Hall C, Poster Board #126
Time: 9:45 – 10:45 a.m.
- Title: "Prospective trial of endocrine therapy alone in patients with estrogen-receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low- risk registry" (Abstract #5BA); J. Sparano (U.S.) – Designated a "Best Abstract" by ECC
Oral Presentation, Presidential Session Location: Hall D1
Time: 5:05 – 5:25 p.m.
About Oncotype DX®
The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The company's flagship product, the Oncotype DX breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the test predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS. With half a million patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX breast cancer tests, visit: www.OncotypeDX.comor www.mybreastcancertreatment.org.
About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with international headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the benefits of the test to physicians, patients and payors. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the ability of test results to change treatment decisions; the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; the risk that the company may not obtain or maintain sufficient levels of reimbursement, domestically or abroad, for its existing tests and any future tests it may develop; the risks of competition; unanticipated costs or delays in research and development efforts; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's quarterly report on Form 10-Q for the year ended June 30, 2015. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
SOURCE Genomic Health, Inc.